Spotlight Innovation subsidiary Celtic Biotech enters into Research Agreement with Emory University

FOR IMMEDIATE RELEASE – July 6, 2015, West Des Moines, Iowa

Spotlight Innovation Inc. (OTCQB: STLT) announces today that its subsidiary Celtic Biotech has entered into a Research Agreement with Atlanta-based Emory University. The Phase I study will be designed and conducted by an Emory University research team with the specific aim of demonstrating that the cell penetrating peptide Crotamine can be made into a suitable radiopharmaceutical for imaging lung cancer tumors with positron emission tomography (PET) in a clinical setting.

Said Dr. Paul Reid, President of Celtic Biotech, “Emory University has a successful track record in the preclinical and clinical development of imaging agents and they represent a one-stop shop for the development of Crotamine for this indication. Crotamine is an important compound in our pipeline of oncology and pain management therapies, and we are pleased that Emory University has agreed to work with us.”

Cris Grunewald, President and CEO of Spotlight Innovation, said, “We are honored to be partnering with an esteemed research institution such as Emory University. We are dedicated to continuing clinical trials for Celtic Biotech’s portfolio of cancer and pain therapeutic products. These products have the potential to reduce treatment costs, increase survivability, and improve the quality-of-life for cancer patients, and we look forward to fulfilling their promise. This clinical study represents another definitive step in our value-building strategy for Celtic Biotech.”

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) specializes in identifying, acquiring and incubating companies that have unique intellectual property (IP) in the medical sector. The Company utilizes relationships with the nation’s leading academic and institutional IP developers to locate promising IP technologies with potential for market share capture. With our support, development, resources and strategic planning expertise, we believe we can develop IP that will have a positive effect on healthcare. We intend to partner with proven sector leaders on commercialization once technologies are fully developed. Additional information available at

About Celtic Biotech Iowa, Inc.

Celtic Biotech Iowa, Inc., a subsidiary of Spotlight Innovation Inc., is developing novel, clinical trial-phase products for the treatment of cancers and pain in humans. Derived from naturally specialized receptor-binding proteins, these products have the potential to reduce treatment costs, increase survivability, and improve the quality of life for cancer patients. Additional information available at

Forward Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Source: Spotlight Innovation Inc.

Press Contact
Rene Erickson
Spotlight Innovation Inc.
[email protected]

Investor Contact
Rudy Barrio
[email protected]